Abrocitinib for treatment of solid facial edema

Solid facial edema (SFE), or Morbihan syndrome, is a rare, disfiguring, and difficult-to-treat condition characterized by the gradual onset of erythema and solid edema affecting the upper portion of the face.1,2 It is considered a complication or late-stage manifestation of rosacea or acne. The involvement of perilymphatic granulomas has been suspected in the pathogenesis of SFE,3,4 and Janus kinase (JAK) inhibitors have recently shown efficacy in treating cutaneous granulomatous diseases.5 We report the cases of 3 patients with SFE who demonstrated substantial improvement after treatment with abrocitinib (JAK 1 inhibitor).